Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Alogliptin, chemically known as (1S)-2-cyano-N-[(1S)-1-cyclopropyl-3-methyl-1-(4-pyridin-3-yl-butyl)amino]butanamide, is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor primarily utilized in the management of type 2 diabetes mellitus. With the CAS number 506397-86-8, this pharmaceutical compound functions by inhibiting the DPP-4 enzyme, which is responsible for the rapid degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preventing the breakdown of these endogenous incretins, Alogliptin effectively enhances their physiological activity, leading to increased glucose-dependent insulin secretion from pancreatic beta cells and suppressed inappropriate glucagon release from alpha cells. This dual mechanism results in improved glycemic control without causing significant hypoglycemia when used as monotherapy, a distinct advantage over sulfonylureas or insulin.
The molecular formula of Alogliptin is C21H26N6O, reflecting its complex organic structure designed for high specificity and oral bioavailability. It is widely marketed under brand names like Nesina and is often prescribed as an adjunct to diet and exercise in patients who cannot achieve adequate blood sugar control with lifestyle modifications alone. Clinically, it offers a favorable safety profile with a low risk of weight gain, making it suitable for long-term therapy in diverse patient populations. Unlike some other antidiabetic agents, Alogliptin does not typically induce gastrointestinal distress or fluid retention associated with thiazolidinediones. Its pharmacokinetic properties allow for once-daily dosing, enhancing patient compliance. Furthermore, studies suggest potential benefits beyond glycemic control, including possible effects on cardiovascular health, although ongoing research continues to explore these avenues comprehensively. As a cornerstone in modern diabetes care, Alogliptin represents a significant advancement in targeted metabolic regulation, offering clinicians a reliable tool to manage chronic hyperglycemia while minimizing adverse events. Its widespread adoption underscores the importance of DPP-4 inhibition in the evolving landscape of antidiabetic therapeutics, providing a balanced approach to achieving therapeutic targets in type 2 diabetes management globally.